China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

[Akeso (9926 HK, BUY, TP HK$58) Company Update]: AK112’s Win Unleashes Change in PD-1/L1 Landscape

What's Behind Akeso's Cadonilimab Price Cut and What's Next?

[Blue Lotus Healthcare Sector Update]: Bottom-Fishing at the Bottom of the Business Cycle

[Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes

[Akeso Inc. (9926 HK) Target Price Change]: Sell off in High-Beta Names Creates Buying Opportunity

Blue Lotus China New Economy Research, Blue Lotus Research Institute

Eric Wen

Blue Lotus China New Economy Research

Equity Bottom-Up

<ul>
<li>Disputable Phase III result of Akeso's (9926 HK) flagship pipeline Ivonescimab (AK112) caused Akeso's share price to drop 28% in three days, reaching the bottom of a year-long trading range;</li>
<li>The fundamental difference of opinions is around Ivonescimab's global prospects against (1) Merck's Keytruda, (2) J&amp;J's Rybrevant, (3) Kelun's SKB264 and domestic prospect against (4) Innovent's IBI305;</li>
<li>Some answers are clear while others are now. What can provide answers are (1) SKB264's Phase III data, and to a lesser degree (2) AK112's head-to-head trial against Keytruda.</li>
</ul>


Disputable Phase III result of Akeso's (9926 HK) flagship pipeline Ivonescimab (AK112) caused Akeso's share price to drop 28% in three days, reaching the bottom of a year-long trading range;
The fundamental difference of opinions is around Ivonescimab's global prospects against (1) Merck's Keytruda, (2) J&amp;J's Rybrevant, (3) Kelun's SKB264 and domestic prospect against (4) Innovent's IBI305;
Some answers are clear while others are now. What can provide answers are (1) SKB264's Phase III data, and to a lesser degree (2) AK112's head-to-head trial against Keytruda.


Is Akeso's Sell-Off a Long Waited Opportunity or a Long Overdue Correction?

Akeso Biopharma Inc

Is Akeso's Sell-Off a Long Waited Opportunity or a Long Overdue Correction?